PUBLISHER: IMARC | PRODUCT CODE: 1451705
PUBLISHER: IMARC | PRODUCT CODE: 1451705
The global eye drops and lubricants market size reached US$ 21.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 31.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.4% during 2024-2032. The growing cases of eye disorders, rising research and development (R&D) activities in the pharmaceutical sector, and increasing popularity of hormone therapy to minimize the risks associated with dry eye syndrome are some of the major factors propelling the market.
Eye drops and lubricants are essential products used for maintaining and improving eye health. They are designed to provide relief from various eye discomforts, lubricate the eyes, and promote overall eye health. They consist of artificial tears and vasoconstrictors, which help to ease redness by constricting the blood vessels in the eyes. They are available in a variety of formulations to address specific eye conditions and symptoms. They are used to prevent dryness, redness, itchiness, and irritation caused by factors, such as dry environments, prolonged screen time, allergies, or certain medical conditions.
At present, the increasing demand for eye drops and lubricants to alleviate symptoms and provide relief from discomfort in the eyes is impelling the growth of the market. Besides this, the rising awareness about the beneficial aspects of using eye drops and lubricants and the necessity of taking proper eye care is contributing to the growth of the market. In addition, the growing popularity of hormone therapy to minimize the risks associated with dry eye syndrome is offering a favorable market outlook. Apart from this, the increasing number of open-angle glaucoma therapeutics provided via retail pharmacies is supporting the growth of the market. Additionally, the rising occurrence of various age-associated eye disorders in the geriatric population is propelling the growth of the market. Moreover, the increasing adoption of technologically advanced methods to manufacture innovative eye drops and lubricants with improved safety and efficacy is bolstering the growth of the market.
Rising cases of eye diseases
The rising prevalence of eye disorders, including dry eye syndrome, conjunctivitis, and glaucoma, is a key driver for the eye drops and lubricants market. Apart from this, prolonged digital device usage, environmental pollution, and changing lifestyles contribute to the growing incidence of these conditions. In addition, conditions like diabetes, hypertension, and obesity, which are linked to lifestyle choices and are on the rise globally, can affect eye health. For instance, diabetic retinopathy is a complication of diabetes that affects the eyes. Moreover, rapid urbanization and increased pollution are contributing to the increase in eye diseases. Exposure to air pollution is linked to conditions like dry eye syndrome and allergic conjunctivitis. As there is an increase in the occurrence of various eye disorders, the demand for eye drops and lubricants to provide relief from discomfort, itching, redness, and dryness associated with these disorders is rising around the world.
Increasing research-related activities
At present, there is an increase in the development of effective eye drops due to the growing prevalence of eye diseases caused by aging, lifestyle changes, and environmental factors. Besides this, with the advent of technology and the consequent increase in screen time, individuals are increasingly susceptible to eye strain and dryness, thereby driving the demand for innovative solutions. In addition, evolving expectations and demands of consumers are prompting researchers to seek novel formulations that provide instant relief and address the underlying causes of eye discomfort. Traditional eye drops often offer temporary relief, necessitating frequent application, and do not adequately address the root causes of dryness or provide long-lasting moisture. Consequently, the growing need for advanced formulations that can provide sustained lubrication and effectively restore the natural tear film to promote ocular comfort and health is encouraging researchers to develop efficient eye drops and lubricants.
Growing utilization of smartphones and tablets
At present, the increasing utilization of various smart devices, including smartphones, tablets, and laptops, is exerting stress on the eyes of users and raising the incidence of dry eye disease in individuals. Besides this, smartphones are equipped with high-resolution screens that emit blue light, which has a shorter wavelength and higher energy compared to other colors on the light spectrum. Excessive exposure to blue light leads to digital eye strain, also called computer vision syndrome. The constant use of smartphones, often accompanied by prolonged periods of staring at screens, exacerbates these symptoms, contributing to the rising prevalence of eye diseases. Furthermore, the excessive use of smartphones is leading to an increase in the occurrence of various eye complications and the use of various eye drops and lubricants.
IMARC Group provides an analysis of the key trends in each segment of the global eye drops and lubricants market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on the type and application.
Antibiotics
Hormones
Artificial Tears
Others
Artificial tears dominate the market
The report has provided a detailed breakup and analysis of the market based on the type. This includes antibiotics, hormones, artificial tears, and others. According to the report, artificial tears represented the largest segment.
Artificial tears are non-prescription, over-the-counter eye drops that are used to treat symptoms associated with dry eyes. They are designed to mimic the natural tears produced by our eyes and are a blend of water, salts, and polymers that enhance viscosity and lubrication. Artificial tears provide immediate symptoms associated with dry eye syndrome, such as burning, irritation, redness, and a sensation of having something in your eyes. Artificial tears also help maintain the health and integrity of the ocular surface. By providing a surrogate for the natural tear film, they ensure the eye remains well-hydrated and nourished, reducing the risk of damage to the cornea.
Eye Diseases
Dry Eye
Glaucoma
Conjunctivitis
Refractive Errors
Others
Eye Care
Eye diseases hold the largest share in the market
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes eye diseases (dry eye, glaucoma, conjunctivitis, refractive errors, and others) and eye care. According to the report, eye diseases (dry eye, glaucoma, conjunctivitis, refractive errors, and others) accounted for the largest market share.
Eye drops and lubricants are significant tools in the management and treatment of a multitude of ocular conditions. The way they help cure eye diseases is multifaceted, depending on the active ingredient in the drops and the nature of the disease. They provide symptomatic relief by mimicking the natural tear film and lubricating the ocular surface. They are also used to treat bacterial infections, such as conjunctivitis (pink eye) or corneal ulcers. These medications contain substances that inhibit the growth of bacteria or kill them outright. They function by interfering with the replication of viruses while limiting the spread of infection and speed up the healing process.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest eye drops and lubricant market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share due to the rising occurrence of dry eye syndrome, glaucoma, age-related macular degeneration, and cataracts among the aging population. Besides this, the prolonged screen time causing digital eye strain and dry eyes among the masses is propelling the growth of the market.
Another contributing aspect is the rising occurrence of eye allergies caused by climate change and rising levels of pollution. In addition, the increasing advancement in eye care treatments is supporting the growth of the market.
Asia Pacific is estimated to expand further in this domain due to the rising utilization of smartphones and laptops to access the internet. In addition, the growing construction of eye hospitals offering efficient eyecare services is positively influencing the market.
Key market players are investing in research operations to innovate and improve their eye drops and lubricants. They are also focusing on developing advanced formulations, ingredients, and delivery systems to enhance the effectiveness and comfort of their products. Top companies are striving to expand their product portfolios by introducing new eye drops and lubricants that cater to different consumer needs. They are also offering specialized products for dry eye relief, allergy relief, redness reduction, contact lens lubrication, and other specific eye care concerns. Leading companies are collaborating with healthcare professionals, including ophthalmologists and optometrists, to gain insights into patient needs and develop products tailored to those needs.
Akorn Operating Company LLC
Alcon
Allergan Plc (AbbVie Inc.)
Bausch & Lomb Incorporated
Bayer AG
Johnson & Johnson
Maya Biotech Private Limited
Prestige Consumer Healthcare Inc.
Rohto Pharmaceutical Co. Ltd.
Sager Pharma Kft
Similasan Corporation
In June 2019, Akorn Operating Company LLC announced the launch of its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, which is used for treating post-operative inflammation following ocular surgery.
In November 2022, Alcon announced the acquisition of Aerie Pharmaceuticals Inc., which will help to bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial items and development pipeline.
In October 2019, Allergan Plc (AbbVie Inc.) announced the launch of three novel over-the-counter REFRESH RELIEVA products comprising a new line of artificial tear formulations that are suitable for contact lens wearers.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.